{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-090113","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.833732+00:00","generated_at":"2026-05-17T06:28:52.202459+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocugen licenses OCU400 gene therapy to Kwangdong for South Korea; $1M upfront, up to $6.5M milestones","bullets":["Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.","$1M upfront; up to $6.5M in regulatory/development milestones plus sales milestones of $1.5M per $15M sales.","Royalty of 25% on net sales; Ocugen to manufacture commercial supply under separate agreement.","Term continues until 20 years after first commercial sale or last valid patent/exclusivity expiry."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-090113","json":"https://secwatch.observer/filing/0001104659-25-090113.json","markdown":"https://secwatch.observer/filing/0001104659-25-090113.md","text":"https://secwatch.observer/filing/0001104659-25-090113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/0001104659-25-090113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/tm2526167d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:28:52.202459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}